Evidence map›Paper›PMID 42835413›Full record

ArticleFrontiers in microbiology2026

Targeted

Sima Talebzadeh, Per Erik Joakim Saris

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sima TalebzadehFaculty of Agriculture and Forestry, Department of Microbiology, University of Helsinki, Helsinki, Finland.
Per Erik Joakim SarisFaculty of Agriculture and Forestry, Department of Microbiology, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inroduction: Emerging evidence links fecal Methods: This study evaluated the inhibitory potential of 32 probiotic and potential probiotic strains against three DSV strains isolated from three individual PD patients. Antimicrobial activity was quantified using agar well diffusion and microplate assays, and the operational minimum inhibitory con centration (MIC₉₀) was determined based on the total crude dry matter content of cell-free supernatants (CFS). Results: All tested lactic acid bacteria (LAB) strains, except Discussion: These findings demonstrate that specific probiotics can target PD-derived DSV, offering a novel strategy for microbiome-based PD management.

Indexed as

antimicrobial activityDesulfovibriogut microbiotaParkinson’s diseaseprobiotics

Identifiers

PMID42835413
PMCPMC13635351

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.